LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients.

    Li, Adam / Erridge, Simon / Holvey, Carl / Coomber, Ross / Barros, Daniela / Bhoskar, Urmila / Crews, Matthieu / Donnelly, Lorna / Imran, Muhammad / Korb, Laura / Mwimba, Gracia / Sachdeva-Mohan, Simmi / Rucker, James J / Sodergren, Mikael H

    International clinical psychopharmacology

    2024  

    Abstract: This study aims to analyze changes in health-related quality of life (HRQoL) and safety in patients with generalized anxiety disorder (GAD) prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). Patients prescribed Adven CBMPs ( ... ...

    Abstract This study aims to analyze changes in health-related quality of life (HRQoL) and safety in patients with generalized anxiety disorder (GAD) prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). Patients prescribed Adven CBMPs (Curaleaf International, UK) for GAD were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in patient-reported outcome measures (PROMs) from baseline up to 12 months, including GAD-7, Single-Item Sleep Quality Scale (SQS), and EQ-5D-5L. Adverse events were recorded using CTCAE version 4.0. A total of 120 patients were identified for inclusion, of which 38 (31.67%), 52 (43.33%), and 30 (25.00%) were prescribed oils, dried flower, and both formulations of CBMP. Associated improvements in GAD-7, SQS, and EQ-5D-5L at 1, 3, 6, and 12 months were observed compared to baseline (P < 0.010). There were 24 (20.00%) patients who reported 442 (368.33%) adverse events, most of which were mild (n = 184, 41.63%) and moderate (n = 197, 44.57%). This study reports an association between initiation of a homogeneous CBMP therapy and improvements in anxiety severity and HRQoL in individuals with GAD. Moreover, therapy was well-tolerated at 12 months follow-up. Further investigation through randomized controlled trials will ultimately be required to determine causation.
    Language English
    Publishing date 2024-02-02
    Publishing country England
    Document type Journal Article
    ZDB-ID 632837-4
    ISSN 1473-5857 ; 0268-1315
    ISSN (online) 1473-5857
    ISSN 0268-1315
    DOI 10.1097/YIC.0000000000000536
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Anticholinergics vs Placebo for Neuroleptic-Induced Parkinsonism.

    Dickenson, Rebecca / Momcilovic, Stefan / Donnelly, Lorna

    Schizophrenia bulletin

    2017  Volume 43, Issue 1, Page(s) 17

    MeSH term(s) Antipsychotic Agents/adverse effects ; Cholinergic Antagonists/pharmacology ; Humans ; Parkinson Disease, Secondary/drug therapy ; Parkinson Disease, Secondary/etiology
    Chemical Substances Antipsychotic Agents ; Cholinergic Antagonists
    Language English
    Publishing date 2017
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 439173-1
    ISSN 1745-1701 ; 0586-7614
    ISSN (online) 1745-1701
    ISSN 0586-7614
    DOI 10.1093/schbul/sbw087
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Haloperidol dose for the acute phase of schizophrenia.

    Donnelly, Lorna / Rathbone, John / Adams, Clive E

    The Cochrane database of systematic reviews

    2013  , Issue 8, Page(s) CD001951

    Abstract: Background: Haloperidol is a benchmark, accessible antipsychotic drug against which the effects of newer treatments are gauged.: Objectives: To determine the best range of doses for haloperidol for the treatment of people acutely ill with ... ...

    Abstract Background: Haloperidol is a benchmark, accessible antipsychotic drug against which the effects of newer treatments are gauged.
    Objectives: To determine the best range of doses for haloperidol for the treatment of people acutely ill with schizophrenia.
    Search methods: We searched the Cochrane Schizophrenia Group Trials Register (February 2010), which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO.
    Selection criteria: We selected studies if they involved people being treated for acute schizophrenia, randomised to two or more dose ranges of non-depot haloperidol, and if they reported clinically meaningful outcomes.
    Data collection and analysis: For this update, we inspected all citations and independently re-inspected a sample of citations in order to ensure reliable selection. We resolved any disagreement by discussion, and where doubt remained, we acquired the full-text article for further inspection. We then ordered papers, and reliably re-inspected and quality assessed the full reports, and extracted data. For homogeneous dichotomous data, we calculated the risk ratio (RR) with 95% confidence intervals (CI) on an intention-to-treat (ITT) basis. We assumed that people who left the study early or were lost to follow-up had a negative outcome. We calculated mean differences (MD) for continuous outcomes that reported ITT, last observation carried forward (LOCF) data. We excluded data if loss to follow-up was greater than 50%.
    Main results: We included 19 trials with 19 different randomised dose comparisons. No studies reported data on relapse rates or quality of life and only one compared low dose (> 1.5 to 3 mg/day) haloperidol to higher dose ranges. Using standard lower dose (> 3 to 7.5 mg/day) did not result in loss of efficacy (no clinically important improvement in global state, versus standard higher dose (> 7.5 to 15 mg/day, n = 48, 1 RCT, RR 1.09, 95% CI 0.7 to 1.8, very-low-quality evidence); versus high dose (> 15 to 35 mg/day, n = 81, 2 RCTs, RR 0.95, 95% CI 0.8 to 1.2, very-low-quality evidence). Doses of haloperidol in the range of > 3 to 7.5 mg/day had a lower rate of development of clinically significant extrapyramidal adverse effects than higher doses (clinically significant extrapyramidal adverse effects, versus standard higher dose, n = 64, 2 RCTs, RR 0.12, 95% CI 0.01 to 2.1, very-low-quality evidence); versus high dose, n = 144, 3 RCTs, RR 0.59, 95% CI 0.5 to 0.8, very-low-quality evidence; versus very high dose (> 35 mg/day, n = 86, 2 RCTs, RR 0.70, 95% CI 0.5 to 1.1, very-low-quality evidence). None of the other comparisons between dose ranges yielded statistically significant differences, but several, particularly with lower dose ranges, were underpowered to detect clinically meaningful differences.
    Authors' conclusions: Noresults were conclusive and all were based on small, short studies of limited quality. However, it would be understandable if clinicians were cautious in prescribing doses in excess of 7.5 mg/day of haloperidol to a person with uncomplicated acute schizophrenia, and if people with schizophrenia were equally reticent to take greater doses. Further research is needed regarding the efficacy and tolerability of the lower dose ranges, especially > 1.5 to 3 mg/day.
    MeSH term(s) Acute Disease ; Antipsychotic Agents/administration & dosage ; Haloperidol/administration & dosage ; Humans ; Randomized Controlled Trials as Topic ; Schizophrenia/drug therapy
    Chemical Substances Antipsychotic Agents ; Haloperidol (J6292F8L3D)
    Language English
    Publishing date 2013-08-28
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't ; Review ; Systematic Review
    ISSN 1469-493X
    ISSN (online) 1469-493X
    DOI 10.1002/14651858.CD001951.pub2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

    Dejnirattisai, Wanwisa / Huo, Jiandong / Zhou, Daming / Zahradník, Jiří / Supasa, Piyada / Liu, Chang / Duyvesteyn, Helen M.E. / Ginn, Helen M. / Mentzer, Alexander J. / Tuekprakhon, Aekkachai / Nutalai, Rungtiwa / Wang, Beibei / Dijokaite, Aiste / Khan, Suman / Avinoam, Ori / Bahar, Mohammad / Skelly, Donal / Adele, Sandra / Johnson, Sile Ann /
    Amini, Ali / Ritter, Thomas G. / Mason, Chris / Dold, Christina / Pan, Daniel / Assadi, Sara / Bellass, Adam / Omo-Dare, Nicola / Koeckerling, David / Flaxman, Amy / Jenkin, Daniel / Aley, Parvinder K. / Voysey, Merryn / Clemens, Sue Ann Costa / Naveca, Felipe Gomes / Nascimento, Valdinete / Nascimento, Fernanda / Fernandes da Costa, Cristiano / Resende, Paola Cristina / Pauvolid-Correa, Alex / Siqueira, Marilda M. / Baillie, Vicky / Serafin, Natali / Kwatra, Gaurav / Da Silva, Kelly / Madhi, Shabir A. / Nunes, Marta C. / Malik, Tariq / Openshaw, Peter J.M. / Baillie, J. Kenneth / Semple, Malcolm G. / Townsend, Alain R. / Huang, Kuan-Ying A. / Tan, Tiong Kit / Carroll, Miles W. / Klenerman, Paul / Barnes, Eleanor / Dunachie, Susanna J. / Constantinides, Bede / Webster, Hermione / Crook, Derrick / Pollard, Andrew J. / Lambe, Teresa / Paterson, Neil G. / Williams, Mark A. / Hall, David R. / Fry, Elizabeth E. / Mongkolsapaya, Juthathip / Ren, Jingshan / Schreiber, Gideon / Stuart, David I. / Screaton, Gavin R. / Conlon, Christopher / Deeks, Alexandra S. / Frater, John / Frending, Lisa / Gardiner, Siobhan / Jämsén, Anni / Jeffery, Katie / Malone, Tom / Phillips, Eloise / Rothwell, Lucy / Stafford, Lizzie / Baillie, J Kenneth / Openshaw, Peter JM. / Carson, Gail / Alex, Beatrice / Andrikopoulos, Petros / Bach, Benjamin / Barclay, Wendy S. / Bogaert, Debby / Chand, Meera / Chechi, Kanta / Cooke, Graham S. / da Silva Filipe, Ana / de Silva, Thushan / Docherty, Annemarie B. / dos Santos Correia, Gonçalo / Dumas, Marc-Emmanuel / Dunning, Jake / Fletcher, Tom / Green, Christoper A. / Greenhalf, William / Griffin, Julian L. / Gupta, Rishi K. / Harrison, Ewen M. / Hiscox, Julian A. / Wai Ho, Antonia Ying / Horby, Peter W. / Ijaz, Samreen / Khoo, Saye / Law, Andrew / Lewis, Matthew R. / Liggi, Sonia / Lim, Wei Shen / Maslen, Lynn / Merson, Laura / Meynert, Alison M. / Moore, Shona C. / Noursadeghi, Mahdad / Olanipekun, Michael / Osagie, Anthonia / Palmarini, Massimo / Palmieri, Carlo / Paxton, William A. / Pollakis, Georgios / Price, Nicholas / Rambaut, Andrew / Robertson, Dave / Russell, Clark D. / Sancho-Shimizu, Vanessa / Sands, Caroline J. / Scott, Janet T. / Sigfrid, Louise / Solomon, Tom / Sriskandan, Shiranee / Stuart, David / Summers, Charlotte / Swann, Olivia V. / Takats, Zoltan / Takis, Panteleimon / Tedder, Richard S. / Thompson, AA Roger / Thomson, Emma C. / Thwaites, Ryan S. / Turtle, Lance CW. / Zambon, Maria / Hardwick, Hayley / Donohue, Chloe / Griffiths, Fiona / Oosthuyzen, Wilna / Donegan, Cara / Spencer, Rebecca G. / Norman, Lisa / Pius, Riinu / Drake, Thomas M. / Fairfield, Cameron J. / Knight, Stephen R. / Mclean, Kenneth A. / Murphy, Derek / Shaw, Catherine A. / Dalton, Jo / Girvan, Michelle / Saviciute, Egle / Roberts, Stephanie / Harrison, Janet / Marsh, Laura / Connor, Marie / Halpin, Sophie / Jackson, Clare / Gamble, C. / Plotkin, Daniel / Lee, James / Leeming, Gary / Wham, Murray / Clohisey, Sara / Hendry, Ross / Scott-Brown, Jas / Shaw, Victoria / McDonald, Sarah E. / Keating, Seán / Ahmed, Katie A. / Armstrong, Jane A. / Ashworth, Milton / Asiimwe, Innocent G. / Bakshi, Siddharth / Barlow, Samantha L. / Booth, Laura / Brennan, Benjamin / Bullock, Katie / Catterall, Benjamin WA. / Clark, Jordan J. / Clarke, Emily A. / Cole, Sarah / Cooper, Louise / Cox, Helen / Davis, Christopher / Dincarslan, Oslem / Dunn, Chris / Dyer, Philip / Elliott, Angela / Evans, Anthony / Finch, Lorna / Fisher, Lewis WS. / Foster, Terry / Garcia-Dorival, Isabel / Gunning, Philip / Hartley, Catherine / Jensen, Rebecca L. / Jones, Christopher B. / Jones, Trevor R. / Khandaker, Shadia / King So, Katharine / Kiy, Robyn T. / Koukorava, Chrysa / Lake, Annette / Lant, Suzannah / Latawiec, Diane / Lavelle-Langham, Lara / Lefteri, Daniella / Lett, Lauren / Livoti, Lucia A. / Mancini, Maria / McDonald, Sarah / McEvoy, Laurence / McLauchlan, John / Metelmann, Soeren / Miah, Nahida S. / Middleton, Joanna / Mitchell, Joyce / Murphy, Ellen G. / Penrice-Randal, Rebekah / Pilgrim, Jack / Prince, Tessa / Reynolds, Will / Ridley, P. Matthew / Sales, Debby / Shaw, Victoria E. / Shears, Rebecca K. / Small, Benjamin / Subramaniam, Krishanthi S. / Szemiel, Agnieska / Taggart, Aislynn / Tanianis-Hughes, Jolanta / Thomas, Jordan / Trochu, Erwan / van Tonder, Libby / Wilcock, Eve / Zhang, J. Eunice / Flaherty, Lisa / Maziere, Nicole / Cass, Emily / Carracedo, Alejandra Doce / Carlucci, Nicola / Holmes, Anthony / Massey, Hannah / Murphy, Lee / McCafferty, Sarah / Clark, Richard / Fawkes, Angie / Morrice, Kirstie / Maclean, Alan / Wrobel, Nicola / Donnelly, Lorna / Coutts, Audrey / Hafezi, Katarzyna / MacGillivray, Louise / Gilchrist, Tammy / Adeniji, Kayode / Agranoff, Daniel / Agwuh, Ken / Ail, Dhiraj / Aldera, Erin L. / Alegria, Ana / Allen, Sam / Angus, Brian / Ashish, Abdul / Atkinson, Dougal / Bari, Shahedal / Barlow, Gavin / Barnass, Stella / Barrett, Nicholas / Bassford, Christopher / Basude, Sneha / Baxter, David / Beadsworth, Michael / Bernatoniene, Jolanta / Berridge, John / Berry, Colin / Best, Nicola / Bothma, Pieter / Chadwick, David / Brittain-Long, Robin / Bulteel, Naomi / Burden, Tom / Burtenshaw, Andrew / Caruth, Vikki / Chambler, Duncan / Chee, Nigel / Child, Jenny / Chukkambotla, Srikanth / Clark, Tom / Collini, Paul / Cosgrove, Catherine / Cupitt, Jason / Cutino-Moguel, Maria-Teresa / Dark, Paul / Dawson, Chris / Dervisevic, Samir / Donnison, Phil / Douthwaite, Sam / Drummond, Andrew / DuRand, Ingrid / Dushianthan, Ahilanadan / Dyer, Tristan / Evans, Cariad / Eziefula, Chi / Fegan, Chrisopher / Finn, Adam / Fullerton, Duncan / Garg, Sanjeev / Garg, Atul / Gkrania-Klotsas, Effrossyni / Godden, Jo / Goldsmith, Arthur / Graham, Clive / Hardy, Elaine / Hartshorn, Stuart / Harvey, Daniel / Havalda, Peter / Hawcutt, Daniel B. / Hobrok, Maria / Hodgson, Luke / Hormis, Anil / Jacobs, Michael / Jain, Susan / Jennings, Paul / Kaliappan, Agilan / Kasipandian, Vidya / Kegg, Stephen / Kelsey, Michael / Kendall, Jason / Kerrison, Caroline / Kerslake, Ian / Koch, Oliver / Koduri, Gouri / Kōśi, Jōrjj / Laha, Shondipon / Laird, Steven / Larkin, Susan / Leiner, Tamas / Lillie, Patrick / Limb, James / Linnett, Vanessa / Little, Jeff / Lyttle, Mark / MacMahon, Michael / MacNaughton, Emily / Mankregod, Ravish / Masson, Huw / Matovu, Elijah / McCullough, Katherine / McEwen, Ruth / Meda, Manjula / Mills, Gary / Minton, Jane / Mirfenderesky, Mariyam / Mohandas, Kavya / Mok, Quen / Moon, James / Moore, Elinoor / Morgan, Patrick / Morris, Craig / Mortimore, Katherine / Moses, S. / Mpenge, Mbiye / Mulla, Rohinton / Murphy, Michael / Nagel, Megan / Nagarajan, Thapas / Nelson, Mark / Norris, Lillian / O’Shea, Matthew K. / Otahal, Igor / Ostermann, Marlies / Pais, Mark / Panchatsharam, Selva / Papakonstantinou, Danai / Paraiso, Hassan / Patel, Brij / Pattison, Natalie / Pepperell, Justin / Peters, Mark / Phull, Mandeep / Pintus, Stefania / Pooni, Jagtur Singh / Planche, Tim / Post, Frank / Price, David / Prout, Rachel / Rae, Nikolas / Reschreiter, Henrik / Reynolds, Tim / Richardson, Neil / Roberts, Mark / Roberts, Devender / Rose, Alistair / Rousseau, Guy / Ruge, Bobby / Ryan, Brendan / Saluja, Taranprit / Schmid, Matthias L. / Shah, Aarti / Shanmuga, Prad / Sharma, Anil / Shawcross, Anna / Sizer, Jeremy / Shankar-Hari, Manu / Smith, Richard / Snelson, Catherine / Spittle, Nick / Staines, Nikki / Stambach, Tom / Stewart, Richard / Subudhi, Pradeep / Szakmany, Tamas / Tatham, Kate / Thomas, Jo / Thompson, Chris / Thompson, Robert / Tridente, Ascanio / Tupper-Carey, Darell / Twagira, Mary / Vallotton, Nick / Vancheeswaran, Rama / Vincent-Smith, Lisa / Visuvanathan, Shico / Vuylsteke, Alan / Waddy, Sam / Wake, Rachel / Walden, Andrew / Welters, Ingeborg / Whitehouse, Tony / Whittaker, Paul / Whittington, Ashley / Papineni, Padmasayee / Wijesinghe, Meme / Williams, Martin / Wilson, Lawrence / Winchester, Stephen / Wiselka, Martin / Wolverson, Adam / Wootton, Daniel G. / Workman, Andrew / Yates, Bryan / Young, Peter

    Cell. 2022 Feb. 03, v. 185, no. 3 p.467-484.e15

    2022  

    Abstract: On 24ᵗʰ November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent ... ...

    Institution OPTIC Consortium
    ISARIC4C Consortium
    Abstract On 24ᵗʰ November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.
    Keywords Severe acute respiratory syndrome coronavirus 2 ; evolution ; neutralization ; pandemic ; vaccines ; SARS-CoV-2 ; Omicron ; variants ; immune evasion ; receptor interaction ; Spike ; RBD
    Language English
    Dates of publication 2022-0203
    Size p. 467-484.e15.
    Publishing place Elsevier Inc.
    Document type Article ; Online
    ZDB-ID 187009-9
    ISSN 1097-4172 ; 0092-8674
    ISSN (online) 1097-4172
    ISSN 0092-8674
    DOI 10.1016/j.cell.2021.12.046
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

To top